Trial reportNature clinical practice. Cardiovascular medicine2009
Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study.
Trial report in Nature clinical practice. Cardiovascular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Stem cell therapy for patients with acute myocardial infarction: a systematic review of clinical trials.Stem cell research & therapy · 2025Pooled it
- Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review.JAMA cardiology · 2016Pooled it
- Stem cell treatment for acute myocardial infarction.The Cochrane database of systematic reviews · 2015Pooled it
- Trial
- Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study.Stem cell research & therapy · 2015Trial
- Combined delivery of bone marrow-derived mononuclear cells in chronic ischemic heart disease: rationale and study design.Clinical cardiology · 2013Trial
- Randomized transcoronary delivery of CD34(+) cells with perfusion versus stop-flow method in patients with recent myocardial infarction: Early cardiac retention of ⁹⁹(m)Tc-labeled cells activity.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2011Trial
- LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.Texas Heart Institute journal · 2010Trial
- Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population.ESC heart failure · 2024Article
- Adipose Stem Cell-Seeded Decellularized Porcine Pericardium: A Promising Functional Biomaterial to Synergistically Restore the Cardiac Functions Post-Myocardial Infarction.Veterinary sciences · 2023Article
- Stem cells treatment in chronic ischemic heart disease: a narrative review.American journal of stem cells · 2023Review
- Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data.Journal of clinical medicine · 2022Article
- Cell-Based HIF1α Gene Therapy Reduces Myocardial Scar and Enhances Angiopoietic Proteome, Transcriptomic and miRNA Expression in Experimental Chronic Left Ventricular Dysfunction.Frontiers in bioengineering and biotechnology · 2022Article
- Stem cells therapy in acute myocardial infarction: a new era?Clinical and experimental medicine · 2021Review
- The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease.Frontiers in cell and developmental biology · 2021Review
- The role of stem cells in treating coronary artery disease in 2018.Indian journal of thoracic and cardiovascular surgery · 2018Review
- Intramyocardial Injection of Stem Cells in Pig Myocardial Infarction Model: The First Trial in Korea.Journal of Korean medical science · 2017Article
- Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials.Analytical cellular pathology (Amsterdam) · 2017Review
- Three dimensional fusion of electromechanical mapping and magnetic resonance imaging for real-time navigation of intramyocardial cell injections in a porcine model of chronic myocardial infarction.The international journal of cardiovascular imaging · 2016Article
- Cell Therapy in Ischemic Heart Disease: Interventions That Modulate Cardiac Regeneration.Stem cells international · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombined intracoronary and intramyocardial administration might improve outcomes for bone-marrow-derived stem cell therapy for acute myocardial infarction (AMI). We compared the safety and feasibility of early and late delivery of stem cells with combined therapy approaches.
methodsPatients with left ventricular ejection fraction less than 45% after AMI were randomly assigned stem cell delivery via intramyocardial injection and intracoronary infusion 3-6 weeks or 3-4 months after AMI. Primary end points were changes in infarct size and left ventricular ejection fraction 3 months after therapy.
resultsA total of 60 patients were treated. The mean changes in infarct size at 3 months were -3.5 +/- 5.1% (95% CI -5.5% to -1.5%, P = 0.001) in the early group and -3.9 +/- 5.6% (95% CI -6.1% to -1.6%, P = 0.002) in the late group, and changes in ejection fraction were 3.5 +/- 5.6% (95% CI 1.3-5.6%, P = 0.003) and 3.4 +/- 7.0% (95% CI 0.7-6.1%, P = 0.017), respectively. At 9-12 months after AMI, ejection fraction remained significantly higher than at baseline in both groups. In the early and late groups, a mean of 200.3 +/- 68.7 x 10(6) and 194.8 +/- 60.4 x 10(6) stem cells, respectively, were delivered to the myocardium, and 1.30 +/- 0.68 x 10(9) and 1.29 +/- 0.41 x 10(9) cells, respectively, were delivered into the artery. A high number of cells was required for significant improvements in the primary end points.
conclusionsCombined cardiac stem cell delivery induces a moderate but significant improvement in myocardial infarct size and left ventricular function.
Indexed as
Identifiers
19002124What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.